ClinicalTrials.gg

Program

Relcobatinib

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by Enliven Therapeutics.

Furthest: phase 3, since Oct 23, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Enliven Therapeutics33 open or runningphase 3since Oct 23, 2026Mar 15, 2022Dec 2027phase 1 · NCT05304377

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 15, 2022First study: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFirst studyNCT05304377 · 250 planned · United States, Australia, Belgium and more
  2. Dec 16, 2024Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06787144 · 21 planned · Japan
  3. Oct 23, 2026Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositivePhase 3 reachedNCT07905183 · 450 planned

Ahead

  1. Dec 2027Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT05304377
  2. Jan 2028Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06787144
  3. Dec 31, 2028Primary completion: phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07905183

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07905183Leukemia, Myelogenous, Chronic, BCR-ABL Positive3Not yet recruitingDec 31, 2028450
NCT06787144Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Japan1RecruitingJan 202821
NCT05304377Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Belgium and more1RecruitingDec 2027250

How it is read

Names in the registry

  • “ELVN-001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.